linjc16/ctgov huggingface dataset:
Imaging of Atherosclerosis With 68Ga-MSA

Study Overview
=================
Brief Summary
-----------------
Despite of intensive efforts, no specific ath¬erosclerosis-targeting agent labeled with positron emitter is not yet available. Fortunately, some scientists made the major advance in the field of clinical atherosclerosis molecular imaging by the metabolic PET reporter agent 18F(fluorine-18)-FDG(Fludeoxyglucose) applied to noninvasively image plaque macrophages in carotid arteries. However, coronary and cerebral arterial segments remain uninterpretable due to metabolic property of 18F-FDG. Applying the character of the terminal mannose residues of MSA binding with the mannose receptors of macrophages in atherosclerosis, we investigate whether 68Ga-MSA can be a novel agent for non-invasive molecular imaging of atherosclerotic lesion in PET.

Official Title
-----------------
Identification of Vascular Inflammatory Image Using a 68Ga-MSA(Gallium-68 Neomannosyl Human Serum Albumin) in Patients With Atherosclerotic Lesions

Conditions
-----------------
Atherosclerosis, Noninvasive Imaging of Atherosclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: acute coronary syndrome(acute myocardial infarction, unstable angina) chronic stable angina control without coronary artery disease Exclusion Criteria: pregnancy, allergy to albumin, chronic inflammatory disease
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| acute coronary syndrome<br>patients with acute myocardial infarction and unstable angina | |
| chronic stable angina<br>patients with chronic stable angina | |
| control<br>control subjects without coronary artery disease | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| comparison of SUV(standard uptake unit) at atherosclerotic plaque of aorta and carotid arteries among 3 groups |  | 1 day at the time of PET(positron emission tomogram) imaging | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| side effect of PET imaging with 68Ga-MSA | any side effects including changes of biochemical values and vital signs | with 7 days after PET imaging | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
positron emission tomography, macrophage, neomannosyl human serum albumin
One-lung Ventilation: Expression of Pulmonary Inflammatory Mediators

Study Overview
=================
Brief Summary
-----------------
One-lung ventilation; organ protection; volatile anesthetics One-lung ventilation has become a common procedure for thoracoscopic surgery. Two hypothesis will be tested in this study: Are inflammatory mediators increased in the re-ventilated lung after short-period pulmonary collapse? Does Sevoflurane influence the production of inflammatory mediators in the re-inflated lung? Therefore, this study will elucidate the potential protective effect of a volatile anaesthetic (sevoflurane) on the production of inflammatory mediators by the respiratory compartment of the lung, i.e. the alveolar epithelium. Trial with immunomodulatory product / biological

Official Title
-----------------
Lung: One-lung Ventilation: Expression of Pulmonary Inflammatory Mediators After Deflation and Re-expansion of the Lung During Thoracic Surgery

Conditions
-----------------
Thoracic Surgery With One-lung Ventilation

Intervention / Treatment
-----------------
* Drug: Sevoflurane/propofol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Thoracic surgery (thoracotomy, thoracoscopy) with one-lung ventilation Exclusion criteria: Immunosuppressive therapy Ongoing inflammatory processes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Sevoflurane/propofol|Sevoflurane/propofol|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| One-lung ventilation measurement in the re-ventilated lung after short-period pulmonary collapse |  | Sep 07 |
Inhospital Resuscitation: Incidence, Causes and Outcome

Study Overview
=================
Brief Summary
-----------------
Define the frequency and survival pattern of cardiac arrests in relation to the hospital day of event and etiology of arrest.

Detailed Description
-----------------
Define the frequency and survival pattern of cardiac arrests in relation to the hospital day of event and etiology of arrest. The study aims to evaluate the outcome of in-hospital cardiac arrests, focusing on the relationship between etiology and outcome and, in particular, in relation to the length of hospitalization prior to the cardiac arrest. The aimed to sought to test the hypothesis that cardiac arrests occurring after longer hospitalizations were associated with lower survival rates and worse neurological outcomes compared to shorter hospitalizations.

Official Title
-----------------
Causes and Outcome of Cardiac Arrest In-a University Hospital

Conditions
-----------------
In-hospital Cardiac Arrest

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cases where the emergency help team is called Exclusion Criteria: Absence of informed consent Lack of data records of patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of in hospital cardiac arrest |  | baseline | 
| neurologic outcome of patients according to Cerebral performance category scale | The Cerebral performance category scale ranges from 1 to 5 with 1 representing intact function and 5 representing brain death. | until six months after return of spontaneous circulation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| causes of intraoperative cardiac arrest among participants/patients | Probable causes of intraoperative cardiac arrest among participants/patients Diabetes, Hypertension, Smoking, Dyslipidemia, Coronary artery disease, Chronic respiratory insufficiency, Chronic heart failure, Chronic renal insufficiency, Chronic hepatic insufficiency, Chronic neurological disease, Cancer. | baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CPR, cardiac arrest, inhospital
Retrospective Review of Anterior and Posterior Cervical, Thoracic, and Lumbar Instrumented Arthrodesis Surgeries

Study Overview
=================
Brief Summary
-----------------
Retrospective review will allow for an evaluation of potential patient- or procedure-related factors that are associated with the development of either radiologic or clinical adjacent-segment pathology.

Detailed Description
-----------------
Spinal arthrodesis can be performed through either anterior, posterior, or lateral approaches for a variety of traumatic, degenerative, or deformity conditions. In recent years, the development of more sophisticated segmental instrumentation techniques and hardware has allowed for incorporation of multiple spinal levels in single settings. The long-term consequences for spinal motion segments adjacent to such fusions remain unknown. The investigators propose to undertake a retrospective case study analysis evaluating both radiologic and clinical parameters indicative of adjacent-segment pathology in patients who have undergone instrumented arthrodesis procedures at Ohio State University, performed by either Dr. Francis Farhadi, James B. Elder, or Gary Rea.

Official Title
-----------------
Proposal for Retrospective Review of Anterior&Posterior Cervical, Thoracic, and Lumbar Instrumented Arthrodesis Surgeries Performed at OSU.

Conditions
-----------------
Spinal Condition

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must have had a Spinal arthrodesis procedure at Ohio State University Exclusion Criteria: NA

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of patients with radiologic evidence of fusion | Radiologic review will include X-Rays, CT, and MRI at pre-surgery, as well as X-rays at 6 weeks, 3, 6, 12, 24, 36, 48 and 60 months post-operatively. | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of patient with clinical evidences of fusions | examples of clinical measurement are Pain Scores and the Visual Analog Scale | 5 years |
Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid Tumors

Study Overview
=================
Brief Summary
-----------------
Study to determine the steady-state pharmacokinetics and urinary excretion of porfiromycin and major metabolites in head and neck cancer and other cancer patients with solid tumors who receive radiation therapy.

Official Title
-----------------
A Phase I Intensive Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid Tumors Who Receive Radiation Therapy

Conditions
-----------------
Head and Neck Neoplasms

Intervention / Treatment
-----------------
* Drug: Porfiromycin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with histologically proven advanced head and neck cancer or other solid tumors undergoing radiation therapy Patients with prior chemotherapy will be considered if chemotherapy occurred more than 30 days prior to this study Patients must be receiving concomitant radiotherapy (RT) Performance status of ≥ 70% on the Karnofsky performance scale (KPS) Must be ≥ 18 years of age Expected survival of at least three months Written informed consent Exclusion Criteria: Patients who meet any of the following clinical laboratory criteria: Granulocyte count of < 2000/mm**3 Platelets < 75,000/mm**3 Serum creatinine > 1.5 times the upper limit of normal Bilirubin > 1.5 times the upper limit of normal Prothrombin time and partial thromboplastin time > 1.5 times the upper limit of normal Women who are pregnant Men and women of child-bearing potential who are unwilling to utilize a medically acceptable method of contraception Patients who have any known bleeding disorder at the discretion of the investigator Presence of any other life-threatening illness, such as unstable angina, severe oxygen dependent chronic obstructive pulmonary disease, or unstable liver or renal disease Treatment with granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor or Interleukin-1l within 30 days prior to the start of RT Patients who have had prior exposure to mitomycin C or porfiromycin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Porfiromycin<br> | Drug: Porfiromycin<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of serum concentrations of the analyte |  | up to 6 hours after drug infusion | 
| Amount of analyte excreted in urine |  | 0-3 and 3-6 hours after infustion |
Tryptophan Metabolism in Kidney Disease

Study Overview
=================
Brief Summary
-----------------
Tryptophan metabolism in kidney disease will be investigated in patients with chronic kidney disease stages (ADOQI 3-5). Tryptophan levels and respective catabolites will be assessed under hemodialysis.

Conditions
-----------------
Chronic Kidney Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic kidney disease (for > 3months) stages (National Kidney foundation/ADOQI): 3-5 Exclusion Criteria: Signs of infection or systemic inflammation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with chronic kidney disease stage 3<br> | |
| patients with chronic kidney disease stage 4<br> | |
| patients with chronic kidney disease stage 5 (ESRD)<br> | |
| Controls (no kidney disease)<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Course of plasma tryptophan level and levels of tryptophan metabolites under standard low-flux hemodialysis. |  | does not apply | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Assessment of tryptophan and tryptophan catabolites and IDO-activity in patients with chronic kidney disease
The Effect of Blood Transfusion on Venoarterial PCO2 Difference in Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
Venoarterial CO2 difference(delta PCO2), lactate, central venous oxygen saturation(ScVO2) will be recorded in several steps in coronary artery bypass graft and valvular cardiac operations. The patients will be divided into two groups as Transfused, and Non-Transfused Groups observationally. The trend of delta CO2, lactate, ScVO2, postoperative creatinine values, postoperative complications and 28 days mortality will be compared.

Detailed Description
-----------------
Preoperative creatinine values, demographic data, comorbidities will be recorded in ASA I-II elective coronary artery and valvular cardiac surgery patients. Intraoperative delta PCO2, lactate, ScVO2 will be recorded in several steps. The patients will be divided into two groups as Transfused, and Non-Transfused Groups observationally. The trend of delta CO2, lactate, ScVO2, postoperative creatinine values, postoperative complications and 28 days mortality will be compared.

Official Title
-----------------
The Effect of Blood Transfusion on Venoarterial PCO2 Difference in Cardiac Surgery

Conditions
-----------------
Cardiac Procedure Complication

Intervention / Treatment
-----------------
* Biological: Blood transfusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elective cardiac surgery, stable cardiac function Exclusion Criteria: Clinical signs of heart failure, symptomatic cerebral or peripheral failure, uncontrolled diabetes mellitus

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Transfused<br>Patients who have blood transfusion during cardiac surgery | Biological: Blood transfusion<br>* The transfusion of erythrocyte suspension<br>|
| Not-Transfused<br>Patients who don't have blood transfusion during cardiac surgery | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complication | The postoperative neurologic, renal, hepatic, respiratory complications | 5 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | mortality | 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
tissue oxygenation
Trends in Incidence and Survivals for Ovarian Germ Cell Tumors: A 27-Year Population-Based Study

Study Overview
=================
Brief Summary
-----------------
Trends in Incidence and Survivals for Ovarian Germ Cell Tumors: A 27-Year Population-Based Study

Detailed Description
-----------------
This is a chart review.

Official Title
-----------------
Trends in Incidence and Survivals for Ovarian Germ Cell Tumors: A 27-Year Population-Based Study

Conditions
-----------------
Ovarian Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Ovarian Germ Cell Tumors in the last 27 years.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Primary Care Physician's Wishes and Influencing Factors Toward Provision of Integrated Health Care

Study Overview
=================
Brief Summary
-----------------
This questionnaire-based study was focused on understanding primary care physician's wish toward provision of integrated health care, associated knowledge and attitude, and analysis of influencing factors affecting their choices.

Detailed Description
-----------------
The population is aging rapidly in Taiwan. It has been estimated that 15 years from now, the elderly population will comprise over 20% of the general population. Within an aging population, the prevalence of chronic illnesses can be expected to increase, and these patients with multiple chronic illnesses will likely need a larger allocation of available resources with the national health care system. In contrast to a highly-specialized medical environment, integrated health care, with its multitude of health and medical services including diagnosis, treatment, convalescence, rehabilitation, and health promotion, can provide a more efficient synergism between the necessary aspects of delivery, supply, management and organization. Literature has shown that multi-disciplinary, well-managed chronic illness management can increase the convenience of patient medical visits and also decrease medical costs. To provide patients with multiple chronic illnesses more suitable, efficient, and higher quality medical care, and to decrease redundant or ill-advised medications or procedures, as well as to encourage medical systems to further incorporate integrated services to advance the ideal of holistic care, the Bureau of National Health Insurance issued the a decree on September 15th, 2009, named Integrated care model and medical system-based integration plan. This questionnaire-based study was focused on understanding primary care physician's wish toward provision of integrated health care, associated knowledge and attitude, and analysis of influencing factors affecting their choices.

Official Title
-----------------
Primary Care Physician's Wishes and Influencing Factors Toward Provision of Integrated Health Care

Conditions
-----------------
Attitude of Health Personnel

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The primary care physicians, who practicing western medicine, with the doctor licenses approved by the Department of Health in Taiwan Exclusion Criteria: The subjects who are unable to complete the survey independently

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Machine Learning Model for Perioperative Transfusion Prediction

Study Overview
=================
Brief Summary
-----------------
This study aimed to develop and interpret a machine learning model to predict red blood cell (RBC) transfusion.

Detailed Description
-----------------
A dataset from a multicenter study involving 6121 patients underwent elective major surgery was analysed. Data concerning patients who received inappropriate RBC transfusion were excluded. Twenty one perioperative features were used to predict RBC transfusion. The data set was randomly split into train and validation sets (70-30). Decision tree, random forest, k-nearest neighbors, logistic regression, and eXtreme garadient boosting (XGBoost) methods were used for prediction. The area under the curves (AUC) of the receiver operating characteristics curves for the machine learning models used for RBC transfusion prediction were compared.

Official Title
-----------------
Development and Interpretation of a Machine Learning Model for Perioperative Transfusion Prediction

Conditions
-----------------
Surgery, Blood Transfusion

Intervention / Treatment
-----------------
* Other: Perioperative blood transfusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult Underwent major elective surgery Exclusion Criteria: Pediatric patients Emergency cases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Perioperative blood transfusion|Perioperative blood transfusion|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients received Red blood cell transfusion | Number of patients received Red blood cell transfusion | Perioperative period | 
| The area under the curve | The the area under the curve of the receiver operating characteristics curves | Perioperative period | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Decision tree, eXtreme garadient boosting, k-nearest neighbors, Logistic regression, Machine learning, Prediction model, Random forest, Red blood cell transfusion, Surgery